AR113881A1 - Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia - Google Patents

Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia

Info

Publication number
AR113881A1
AR113881A1 ARP180103328A ARP180103328A AR113881A1 AR 113881 A1 AR113881 A1 AR 113881A1 AR P180103328 A ARP180103328 A AR P180103328A AR P180103328 A ARP180103328 A AR P180103328A AR 113881 A1 AR113881 A1 AR 113881A1
Authority
AR
Argentina
Prior art keywords
methods
compositions
treatment
immune disorders
blautia strain
Prior art date
Application number
ARP180103328A
Other languages
English (en)
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of AR113881A1 publication Critical patent/AR113881A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se proporcionan en el presente métodos y composiciones relacionados con la cepa A de Blautia útiles como agentes terapéuticos.
ARP180103328A 2017-11-14 2018-11-14 Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia AR113881A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762585782P 2017-11-14 2017-11-14

Publications (1)

Publication Number Publication Date
AR113881A1 true AR113881A1 (es) 2020-06-24

Family

ID=64746632

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103328A AR113881A1 (es) 2017-11-14 2018-11-14 Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia

Country Status (7)

Country Link
US (2) US10493113B2 (es)
EP (1) EP3710023A1 (es)
JP (1) JP2021502964A (es)
CN (1) CN111601610A (es)
AR (1) AR113881A1 (es)
TW (1) TW201936203A (es)
WO (1) WO2019099482A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2755815T3 (es) 2016-09-13 2020-04-23 Allergan Inc Composiciones de toxina de Clostridium no proteicas estabilizadas
US11241461B2 (en) * 2017-08-29 2022-02-08 Evelo Biosciences, Inc. Treating cancer using a blautia strain
EP3710023A1 (en) * 2017-11-14 2020-09-23 Evelo Biosciences, Inc. Compositions and methods for treating disease using a blautia strain
WO2019152667A1 (en) * 2018-01-31 2019-08-08 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using lachnospiraceae bacteria
BR112021000315A2 (pt) * 2018-07-11 2021-08-03 Actym Therapeutics, Inc. cepas bacterianas imunoestimulantes modificadas geneticamente e seus usos
JP2022517268A (ja) * 2019-01-16 2022-03-07 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 免疫チェックポイント阻害剤関連大腸炎を処置するための方法および組成物
TW202108153A (zh) * 2019-05-10 2021-03-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
WO2020252149A1 (en) * 2019-06-11 2020-12-17 Evelo Biosciences, Inc. Processed microbial extracellular vesicles
CN112442455B (zh) * 2019-09-03 2022-04-01 北京量化健康科技有限公司 具有防治高血脂症功能的布劳特氏菌以及产品组合物及其制备方法和应用
CN111304120B (zh) * 2020-02-24 2021-07-23 浙江大学 Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用
EP4157297A4 (en) 2020-05-28 2024-04-10 Trench Therapeutics Inc RESPIRATORY MEDICINES
JP2023530888A (ja) * 2020-06-11 2023-07-20 エヴェロ バイオサイエンシズ，インコーポレーテッド フルニエレラ・マシリエンシス（Ｆｏｕｒｎｉｅｒｅｌｌａ ｍａｓｓｉｌｉｅｎｓｉｓ）を用いて疾患及び障害を治療するための組成物及び方法
US20230263838A1 (en) * 2020-06-11 2023-08-24 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using oscillospiraceae microbial extracellular vesicles
TW202216178A (zh) * 2020-06-11 2022-05-01 美商艾弗洛生物科技股份有限公司 使用巨型球菌屬物種治療疾病及障礙之組成物及方法
CN113842497B (zh) * 2021-09-28 2022-05-17 太原理工大学 一种具有光控抗菌和自愈合功能的CuS@Cur杂化水凝胶敷料的制备方法
CN114225024B (zh) * 2021-12-29 2022-08-19 山东健袖生态科技有限公司 一种用于治疗疾病的益生菌药物
WO2023192360A1 (en) * 2022-03-31 2023-10-05 Incelldx, Inc. Methods of treating a subject for post-treatment lyme disease (ptld) and compositions for use in the same
WO2023205651A2 (en) * 2022-04-19 2023-10-26 Cedars-Sinai Medical Center Methods of treating and diagnosing fatty liver disease
CN114806979A (zh) * 2022-06-29 2022-07-29 杭州师范大学附属医院(杭州市第二人民医院) 一种治疗非酒精性脂肪性肝病的益生菌复合物及其应用
CN116254198B (zh) * 2023-01-05 2024-03-26 中国科学院微生物研究所 一种布劳特氏菌及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
JP6464142B2 (ja) 2013-03-14 2019-02-06 セラバイオーム，エルエルシー プロバイオティクス生物及び／又は治療剤の標的化胃腸管デリバリー
US20160120915A1 (en) 2013-06-10 2016-05-05 New York University Methods for manipulating immune responses by altering microbiota
AU2015353465B2 (en) * 2014-11-25 2021-07-29 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and GVHD
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US9492473B2 (en) 2015-01-26 2016-11-15 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
CN116270718A (zh) * 2015-04-23 2023-06-23 Dsm营养产品有限责任公司 聚糖治疗剂和治疗方法
CN115364122A (zh) * 2015-06-15 2022-11-22 4D制药研究有限公司 包含细菌菌株的组合物
JP7088827B2 (ja) * 2015-08-24 2022-06-21 ニューバイヨタ エルエルシー 糞便由来細菌集団を使用する腸内毒素症の治療システム及び方法
CN107083339B (zh) * 2017-03-01 2020-02-14 华中农业大学 防治仔猪腹泻的复合益生菌制剂及其制备方法和应用
EP3710023A1 (en) 2017-11-14 2020-09-23 Evelo Biosciences, Inc. Compositions and methods for treating disease using a blautia strain

Also Published As

Publication number Publication date
US20190216862A1 (en) 2019-07-18
CN111601610A8 (zh) 2023-07-21
US20200030389A1 (en) 2020-01-30
WO2019099482A1 (en) 2019-05-23
US10493113B2 (en) 2019-12-03
EP3710023A1 (en) 2020-09-23
CN111601610A (zh) 2020-08-28
JP2021502964A (ja) 2021-02-04
US10702561B2 (en) 2020-07-07
TW201936203A (zh) 2019-09-16

Similar Documents

Publication Publication Date Title
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CO2020007142A2 (es) Composiciones y métodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
EA201691582A1 (ru) Новые фармацевтические препараты
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
GT201700072A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
CR20170060A (es) Anticuerpos anti tigit
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CR20160352A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201991997A1 (ru) Комбинированная терапия
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2017008423A (es) Formulaciones transdérmicas.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2018005232A (es) Anticuerpos anti-cd3 novedosos y sus usos.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.

Legal Events

Date Code Title Description
FB Suspension of granting procedure